Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06515730 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

Study acronym: RESOLVE-AMI
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Oct 1, 2027 to Apr 8, 2028
    • Start date changed from estimate of Oct 1, 2024 to Apr 8, 2025
    • Study sites: 0 to 16
    • Collaborators expanded, about 15 words
  2. Primary endpoint revised
    • Secondary endpoints revised (7)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.
Trial Details
NCT Number NCT06515730
Lead Sponsor Karolinska Institutet
Collaborators: Karolinska Trial Alliance, Swedish Heart Lung Foundation, The Swedish Research Council, Stockholm County Council ALF/PPG
Conditions
(from sponsor)		 Left Ventricular Thrombus, Acute Myocardial Infarction
Enrollment 212 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov